Swiss National Bank boosted its stake in shares of Flexion Therapeutics Inc (NASDAQ:FLXN) by 33.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,911 shares of the specialty pharmaceutical company’s stock after acquiring an additional 12,000 shares during the quarter. Swiss National Bank owned 0.13% of Flexion Therapeutics worth $1,200,000 as of its most recent SEC filing.
A number of other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in Flexion Therapeutics by 5.9% during the second quarter. Vanguard Group Inc. now owns 1,054,464 shares of the specialty pharmaceutical company’s stock worth $21,321,000 after acquiring an additional 59,143 shares in the last quarter. Peregrine Capital Management LLC raised its stake in Flexion Therapeutics by 11.4% during the fourth quarter. Peregrine Capital Management LLC now owns 662,875 shares of the specialty pharmaceutical company’s stock worth $16,598,000 after acquiring an additional 67,664 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in Flexion Therapeutics by 53.6% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 165,222 shares of the specialty pharmaceutical company’s stock worth $4,138,000 after acquiring an additional 57,672 shares in the last quarter. Gagnon Securities LLC acquired a new position in Flexion Therapeutics during the third quarter worth $3,490,000. Finally, Russell Investments Group Ltd. raised its stake in Flexion Therapeutics by 2,458.8% during the third quarter. Russell Investments Group Ltd. now owns 127,430 shares of the specialty pharmaceutical company’s stock worth $3,081,000 after acquiring an additional 122,450 shares in the last quarter. Hedge funds and other institutional investors own 94.71% of the company’s stock.
Shares of Flexion Therapeutics Inc (NASDAQ:FLXN) opened at $27.06 on Wednesday. The company has a current ratio of 13.02, a quick ratio of 12.96 and a debt-to-equity ratio of 0.58. Flexion Therapeutics Inc has a 1-year low of $16.51 and a 1-year high of $32.25.
Several research analysts have issued reports on FLXN shares. BidaskClub lowered Flexion Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, January 20th. ValuEngine upgraded Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Berenberg Bank assumed coverage on Flexion Therapeutics in a report on Thursday, February 1st. They set a “buy” rating and a $42.00 target price on the stock. Zacks Investment Research cut Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. Finally, BMO Capital Markets restated an “outperform” rating and set a $36.00 target price (down previously from $37.00) on shares of Flexion Therapeutics in a report on Friday, March 9th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. Flexion Therapeutics currently has a consensus rating of “Buy” and an average price target of $99.00.
ILLEGAL ACTIVITY WARNING: “Flexion Therapeutics Inc (FLXN) Holdings Lifted by Swiss National Bank” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/03/14/flexion-therapeutics-inc-flxn-holdings-lifted-by-swiss-national-bank.html.
About Flexion Therapeutics
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.